Oncology & Cancer

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who ...

page 12 from 40